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Introduction
In 1993 Ernest Beutler wrote an eloquent letter to the 
editor of the American Journal of Human Genetics high-
lighting the deﬁ   ciencies of the systems then used to 
describe DNA variants [1]. Th   at same year, the editor of 
Human Mutation invited Arthur Beaudet and Lap-Chee 
Tsui to produce a nomenclature for variants in genes and 
proteins [2]. From these simple beginnings, the last 17 
years have borne witness to the steady development of 
the nomenclature used to describe sequence variation 
that is now maintained under the auspices of the Human 
Genome Variation Society (HGVS) [3,4]. To some, the 
present nomenclature may seem like an arcane art-form 
jealously guarded by zealots. Th   is may have been a valid 
criticism in the past, but advances in human genetics 
mean that embracing the nomenclature fully is now 
essential. With the completion of the human genome 
sequence, the number of known variants has expanded 
dramatically, with many identiﬁ   ed as being associated 
with medical conditions. For such variants, especially in 
the clinical setting, the need to describe them syste-
matically is paramount [5-7].
Reference DNA sequences and their limitations
A crucial element of variant nomenclature is the refer-
ence DNA sequence with respect to which a variant is 
described. Ideally, the sequence should have been 
submitted to a primary DNA sequence database and be 
identiﬁ  ed by an accession number and its version. For the 
most part, this requirement is complied with nowadays, 
though the quality of the sequence data is sometimes 
questionable. For some genes, the de facto reference 
sequences were established before the advent of high-
throughput sequencing technologies. Intron and inter-
genic sequence data were often less reliable than those of 
the exons for these legacy sequences due to the deﬁ  ciency 
of read-depth coupled with the lack of corroboration of 
the DNA sequence against a corresponding protein. At 
the start of the millennium, recognizing the need for 
Abstract
As our knowledge of the complexity of gene 
architecture grows, and we increase our understanding 
of the subtleties of gene expression, the process of 
accurately describing disease-causing gene variants 
has become increasingly problematic. In part, this is 
due to current reference DNA sequence formats that 
do not fully meet present needs. Here we present the 
Locus Reference Genomic (LRG) sequence format, 
which has been designed for the specifi  c purpose 
of gene variant reporting. The format builds on 
the successful National Center for Biotechnology 
Information (NCBI) RefSeqGene project and provides 
a single-fi  le record containing a uniquely stable 
reference DNA sequence along with all relevant 
transcript and protein sequences essential to the 
description of gene variants. In principle, LRGs can 
be created for any organism, not just human. In 
addition, we recognize the need to respect legacy 
numbering systems for exons and amino acids and 
the LRG format takes account of these. We hope that 
widespread adoption of LRGs - which will be created 
and maintained by the NCBI and the European 
Bioinformatics Institute (EBI) - along with consistent 
use of the Human Genome Variation Society (HGVS)-
approved variant nomenclature will reduce errors in 
the reporting of variants in the literature and improve 
communication about variants aff  ecting human health. 
Further information can be found on the LRG web site 
(http://www.lrg-sequence.org).
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technology Information (NCBI) established a database of 
curated non-redundant reference sequences of genomes, 
transcripts and proteins known as RefSeq [8,9]. Until 
recently, most human genomic DNA sequences 
represented in RefSeq have been of genomes rather than 
individual genes. Consequently, the reporting of variants 
in genomic DNA coordinates using RefSeq genomic 
contig sequences has been cumbersome, especially if the 
gene of interest lies on the reverse strand. For example, 
the human COL1A1 gene is the reverse complement of 
bases 13535609 to 13553152 in the RefSeq record 
NT_010783.15. Beginning in 2007, RefSeq has been 
extended to embrace reference sequences for individual 
genes through the creation of RefSeqGene records [10]. 
Many authors still prefer to report intronic sequence 
variants in terms of cDNA coordinates (for example, 
c.2451+77C>T, or the now deprecated format, 
IVS36+77C>T), even though the nomenclature to do so is 
somewhat awkward. However, the use of cDNA coordi-
nates is permitted with RefSeqGene reference sequences.
In spite of these welcome developments, users of these 
sequences must be aware of the update policies of public 
sequence databases. Th   ere are two types of modiﬁ  cation 
to a public sequence record: changes to the sequence, or 
changes to the annotation or description of that 
sequence. Th   e latter type of change is reﬂ  ected only by a 
change to the modiﬁ  cation date of the record, and will be 
changed if the gene symbol changes, citations associated 
with the record change, or the position of features (such 
as the coordinates of exons) within that sequence are 
revised. Th  e former type of change - that is, to the se-
quence itself - results in the incrementing of the version 
of the sequence. For example, the sequence of the desmo-
glein 2 gene, DSG2, was revised from version 
NG_007072.1 to version NG_007072.2 in December 
2007. In May 2008, re-interpretation of the mRNA 
coding regions of the sequence of NG_007072.2 resulted 
in a change of version number for the corresponding 
RefSeq mRNA record for DSG2 from NM_001943.2 to 
NM_001943.3 though no change to the RefSeq protein 
record NP_001934.2 was necessary. Th  e RefSeqGene 
genomic DNA record and the RefSeq protein record both 
retained the same version numbers as before, but the 
RefSeq mRNA record version was incremented. Anec-
dotal evidence, especially from journal editors, suggests 
that these issues are poorly understood by researchers 
who fail to mention the version number of reference 
sequences that they have used as the basis for reporting 
sequence variants. Variant reports that do not clearly 
deﬁ  ne the version of the used reference sequence might 
have ambiguous interpretations.
Failure to fully embrace the issues surrounding version-
ing of reference sequences can lead to inconsistency of 
variant descriptions from one generation of patients to 
the next. An individual testing positive for a given variant 
today may have children who, years later, wish to seek 
genetic counseling and be tested for that same variant. To 
avoid any misunderstanding or confusion by the 
counselor and the staﬀ   of the diagnostic laboratory, it is 
essential that changes to reference DNA sequences are 
closely monitored by these parties to militate against the 
possibility of a change of description for the tested 
variant (see Box 1 for a hypothetical example).
Another limitation is that current reference sequences 
may not represent all transcripts that arise through the 
use of distinct transcription start sites, alternative splic-
ing, or polyadenylation signals (Box 2). Currently, genomic 
reference sequences do not necessarily record all of the 
known mRNAs, focusing instead on information con-
cern  ing the single most abundant mRNA. Ideally, a 
reference sequence for a gene would include all relevant 
spliced transcripts necessary for variant reporting, 
reducing the risk that an eﬀ   ect of the variant on an 
alternatively spliced transcript might be missed.
A further limitation is that the present annotation 
scheme does not take account of well-established legacy 
Box 1. Nomenclature problems because of reference 
sequence versioning
A clinical genetics centre treats Jenny, a patient with a family 
history of the RP10 form of autosomal dominant retinitis 
pigmentosa caused by a variant in the IMPDH1 gene. The 
variant was initially found in her father some time ago and is 
described in a paper published just before he was diagnosed 
with the disease. The paper cites the GenBank RefSeq mRNA 
record NM_000883 when describing the structure of the gene. 
The variant is described using a nucleotide number from 
NM_000883 and a codon number from the translation product 
of that transcript. However, the version number of the GenBank 
record is not given in the paper and now, when the laboratory 
looks in GenBank (by following a hyperlink to NM_000883 given 
in the online version of the paper) they fi  nd that the current 
version is NM_000883.3, with a date stamp in March 2010. The 
exon structure of the gene was revised in 2003 and this resulted 
in the base, codon and exon numberings being changed. The 
variant reported in the literature is therefore no longer found at 
the expected location in the mRNA and protein sequences.
Laboratories specializing in this gene know that the numbering 
relative to the start codon has changed and recognize this as 
a potential source of error. Considerable eff  ort is required to 
translate data in published papers and databases between 
diff  erent versions of reference sequences to gather the 
information needed to analyze cases like Jenny’s. This extra 
complexity means that the service may take longer and be 
more expensive than it otherwise might be. Unfortunately, 
new variants in the IMPDH1 gene are still being described in 
the literature without specifying the version of the reference 
sequence.
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been used in the past, to number features such as exons 
or amino acids. Th  e globins and the collagens provide 
excellent examples of legacy systems (Box 3). Ideally, 
reference sequences would be annotated in a fashion that 
would allow for veriﬁ  cation of variants reported using 
either legacy or HGVS-compliant nomenclatures.
To address these limitations, a meeting sponsored and 
organized by the multi-institute European Union-funded 
GEN2PHEN project [11] was held, with representatives 
of GEN2PHEN (Genotype-To-Phenotype Databases 
Project), European Bioinformatics Institute (EBI) [12] 
and NCBI [13] in attendance, to discuss the speciﬁ  cation 
for stable reference genomic DNA sequences better 
suited to the task of reporting variants. Th  e  participants 
were geneticists, bioinformaticians, clinicians and Locus-
speciﬁ   c Database (LSDB) curators. In advance of the 
meeting, a survey was conducted by GEN2PHEN with 
the help of the HGVS [14] to assess the views of the 
curators of LSDBs.
Th  e primary goal of the meeting was to create a 
universally acceptable standard: a new speciﬁ  cation for 
human genomic DNA reference sequences that would 
address the shortcomings of non-standardized reporting 
resulting from a variety of issues. Th   ese include the lack 
of universally agreed genomic reference sequences for 
some genes even though mRNA, expressed sequence tag 
and genomic assembly records already exist. Sometimes, 
there are DNA sequence inconsistencies between existing 
ad hoc genomic reference sequences (where no 
RefSeqGene record has yet been created) and their NCBI 
RefSeq mRNA sequence counterparts. Inconsistent and 
incomplete (and sometimes outdated and inappropriate) 
annotation of existing ad hoc reference sequences and 
Box 2. Genes with multiple spliced transcripts
Most human genes undergo alternative splicing, and perhaps 
one of the most extreme examples is that of the calcitonin 
gene (CALCA), which produces two distinct peptide-hormone 
products: calcitonin (CT) in the thyroid gland and α-calcitonin 
gene-related peptide (α-CGRP) in the brain [35]. The two mature 
peptides have no amino acid sequence in common and arise 
from translation of alternatively spliced mRNAs. CT and α-CGRP 
are represented in RefSeq mRNA records NM_001033952 and 
NM_001033953, respectively, for the CALCA gene. The LRG record 
LRG_13 has been created for this gene.
The INK4a/ARF multifunctional tumor-suppressor locus [36] 
(CDKN2A) provides an additional example of the need to record 
all clinically relevant transcripts. The gene comprises four exons 
whose transcripts are alternatively spliced and encode both the 
p16INK4a and p14ARF tumor-suppressor proteins. The unexpected 
feature of this gene is that alternative fi  rst exons used by the two 
major transcripts result in the shared exon 2 being translated 
in diff  erent reading frames. The LRG record LRG_11 has been 
created for this gene.
Box 3. Legacy numbering schemata
The amino acid sequence of several human globin chains [37] 
was determined in the late 1950s and early 1960s by direct 
protein sequencing prior to the advent of gene cloning and 
DNA sequencing. In these original sequences, the fi  rst amino 
acid of the human α-, β- and δ-globins is valine and that of 
γ-globin is glycine. However, HGVS nomenclature numbers the 
amino acids beginning with the methionine encoded by the 
initiation codon. Consequently, the sickle-cell disease β-globin 
variant, in which glutamic acid is replaced by valine, should be 
reported as being at position 7, rather than 6, according to HGVS 
recommendations. Indeed, this variant is still described in OMIM 
(Online Mendelian Inheritance in Man) [38] and in the HbVar 
database for hemoglobin variants thalassemia mutations [39,40] 
in terms of the legacy amino acid numbering scheme.
Even though non-standard, the legacy numbering of the globin 
amino acids is well recognized by experts in the fi  eld. However, 
this is not true for newcomers or students who may blindly 
assume that standards are being applied and may become 
either completely lost or waste valuable time sorting out the 
problem. The same is also true in the case of phosphoglycerate 
kinase 1 (PGK, encoded by the PGK1 gene), where considerable 
confusion has arisen from describing variants in relation to 
alterations to the known mature amino acid sequence [41]. 
Again, the issue arises because PGK is one of the few enzymes in 
which variants were characterized at the amino acid level prior 
to DNA sequencing being widely used.
The collagens also provide excellent examples of legacy 
numbering schemes. Because of the lure of the characteristic 
triple-helical nature of the collagens, numbering of the amino 
acids was established decades ago with the fi  rst glycine of the 
(Gly-X-Y)n-repeat region being designated as amino acid number 
1. In addition, when the fi  rst genomic DNA clones were isolated, 
exons were initially numbered in the 3’ to 5’ direction, a lack of full-
length cDNA clones hampering the determination of the exact 
number of exons. Consequently, the fi  rst osteogenesis imperfecta 
variant that was characterized was reported as being in exon 1 of 
the COL1A2 gene, which encodes the α2 chain of type I collagen 
[42]. In fact, the gene is now known to comprise 52 exons and the 
variant lies in exon 52 using conventional numbering. However, 
other exon-numbering anomalies remain. The COL1A1 and 
COL1A2 genes that encode the alpha chains of type I collagen 
are evolutionarily related but COL1A1 has a single exon that 
corresponds to exons 33 and 34 of COL1A2. This single exon is 
known as exon 33/34 [43] and the designation, which is more 
than 20 years old, is still widely used in the current literature.
A further issue is the discovery of additional exons in genes where 
an exon-numbering scheme has already been established. This 
has resulted in the opioid receptor, mu 1 gene (OPRM) having 
exons designated O, X and Y, with exons 3 and 5 divided into 
two and fi  ve sub-regions, respectively [44], and the cystic fi  brosis 
transmembrane conductance regulator gene (CFTR) having exons 
designated 6a, 6b, 14a, 14b, 17a and 17b [45].
Dalgleish et al. Genome Medicine 2010, 2:24 
http://genomemedicine.com/content/2/4/24
Page 3 of 7missing annotation of clinically relevant transcripts is an 
additional problem. Present sequence record systems do 
not provide support for legacy amino acid and exon 
numbering schemes. Finally, the new standard needed to 
address the lack of understanding of the signiﬁ  cance of 
‘versioning’ of sequence data.
Th   e principles guiding the discussions with respect to 
the speciﬁ  cations for genomic reference sequences were 
threefold. First, the sequences need not represent real 
alleles of genes: they can be composites that provide a 
practical working framework for the reporting of 
variants. Second, research or diagnostic laboratories, 
LSDB curators, mutation consortia, and so on that have a 
direct interest in given genes will have the ﬁ  nal say in 
deﬁ   ning the sequences and their annotation. Th  ird, 
stability of the sequences, their core annotation, and their 
identiﬁ  ers is essential to ensure consistency of variant 
reporting over time frames of many decades.
Th   e agreed solution was the concept of an LRG (Locus 
Reference Genomic) [15], which builds on the initial 
ideas from NCBI for RefSeqGene. LRGs will only be 
created in response to demand from the community 
which, in practice, is likely to be from LSDB curators or 
from diagnostic laboratories. LRGs are not restricted to 
protein coding genes, but will be created for any region of 
the genome within which sequence variation needs to be 
recorded, including regulatory regions that encode 
RNAs. However, the mitochondrial genome is explicitly 
excluded as its sequence (RefSeq NC_012920.1) and 
variation is already managed by MitoMap [16]. Th  e  LRG 
system provides a genomic DNA sequence representation 
of a single gene that is idealized, has a permanent ID 
(with no versioning), and core content that never changes 
(that is, nucleotide sequence, transcripts, exons, start and 
stop codon positions). Th  is core annotation will be 
known as the ‘ﬁ  xed-annotation layer’. Although LRGs are 
created for single genes, some might encompass all, or 
part, of overlapping or adjacent genes, as currently 
happens with RefSeqGene records. Th  e  LEPRE1 (leucine 
proline-enriched proteoglycan (leprecan) 1) LRG 
(LRG_5) also includes part of the C1orf50 (chromosome 
1 open reading frame 50) gene, which is encoded on the 
opposite strand. A separate LRG will be created for 
C1orf50 if there is a request from the community.
Additional annotations, known as the ‘updatable-anno-
tation layer’, that may change with time (each item 
carrying its own date stamp) will provide ancillary infor-
ma  tion about a gene. Such annotations will include 
details of additional transcripts and information for 
mapping the LRG sequence onto genome assemblies (for 
example, currently NCBI 36 and Genome Reference 
Consortium Human (GRCh) 37) as well as cross-
referencing of features in the ﬁ  xed-annotation layer to 
legacy coordinate systems.
More than one LRG can be created for a region of 
interest, should the need arise. If essential changes to any 
of the core sequence data are required, such as the need 
to include a newly discovered upstream exon, a new LRG 
record will be generated with a new ID. Sequence 
variants may be validly expressed with reference to the 
original LRG (which will not be retired) or to its 
replacement. An LRG provides a stable sequence and 
numbering system against which samples can be com-
pared and variation be reported. Although annotation is 
provided, the LRG is not intended to aggregate and 
report all known variants.
Variation will be reported using HGVS nomenclature 
[4] and the use of an LRG as the reference standard 
supports all coordinate systems: using genomic DNA 
coordinates, LRG_1:g.8463G>C is equivalent to 
NG_007400.1:g.8463G>C; using coding DNA coordi  nates, 
LRG_1t1:c.572G>C is equivalent to NM_000088.3:c.572G>C; 
using protein coordinates, LRG_1p1:p.Gly191Ala is equi-
va  lent to NP_000079.2:p.Gly191Ala. As a feature of the 
LRG project, the coordinate system of a RefSeqGene that 
matches an LRG will be so indicated and will not be 
changed.
LRGs aﬀ  ord three key improvements in comparison 
with RefSeqGene records. LRGs provide a ‘one-stop’ 
sequence record for a gene (with a single accession 
number) comprising sequences for the gene itself, all of 
the transcripts essential for the reporting of sequence 
variants, and the corresponding predicted proteins 
translated from each transcript. Th  e locking of the 
sequences within the LRG means that ‘version-control’ is 
not an issue in the reporting of sequence variants. No 
sequence (genomic DNA, mRNA or protein) within the 
ﬁ  xed layer will ever be changed or removed. Finally, the 
inclusion of the necessary data facilitates reference to 
features, such as exons or amino acids, using legacy 
numbering or naming schemes.
Implementing LRGs
NCBI continues to identify genes of clinical interest and 
create RefSeqGene records [10]. In March 2010, 
RefSeqGene sequences were available for more than 
2,800 genes and many of these are already in use in 
LSDBs. To ease the transition towards the use of LRGs, 
they will be created from any pre-existing RefSeqGene 
record. Th   e goal is to maximize the similarities. When a 
RefSeqGene record is assigned an LRG accession, it 
means that the sequence, transcripts, proteins and exons 
are identical for that version of the RefSeqGene and the 
LRG. In other words, it will make no diﬀ  erence if variants 
are reported in LRG or RefSeqGene coordinates.
XML was chosen for exchanging and storing LRGs 
because of its ease of extensibility and validation as well 
as its natural hierarchical structure, which lends itself 
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numerous existing programmatic tools for deﬁ  ning, 
vali  dat  ing, parsing and transforming XML. Th  e XML 
schema is deﬁ  ned using Relax NG [17] and is available 
on the EBI FTP site [18]. XSLT style-sheets have been 
produced that will transform the XML into more user-
friendly HTML or plain text. Th  ese are also available 
from the FTP site.
Th   e LRG ﬁ  le has separate XML sections for the ﬁ  xed-
annotation and updatable-annotation layers. Within the 
tags for the ﬁ  xed layer are the genomic sequence and 
transcripts that deﬁ   ne the LRG, together with the 
corresponding cDNA sequence, amino acid sequence 
and exon coordinate markup. Th   e updatable section con-
tains database cross-references, reports of any over-
lapping LRGs, detailed information on how the LRG 
maps to the human genome assembly and information to 
map systematic exon and amino acid coordinates onto 
their legacy equivalents.
LRGs will be compiled and maintained by the NCBI 
and EBI. Th   is will ensure that the data contained in LRGs 
are accurate and consistent with data in other existing 
sequence records. Th   e key involvement of these organiza-
tions means that the LRG format has an assured long-
term future on which users can rely beyond the end of 
the GEN2PHEN project.
Downloading and viewing LRGs
Th  e LRG website [15] provides access to existing LRG 
records and mechanisms for requesting new LRGs. Before 
making a request, it is advisable that users familiarize 
themselves with the complete LRG speciﬁ  cation  [19], 
which is available on the LRG website, and feedback is 
invited on any aspect of the speciﬁ  cation.
To facilitate viewing of LRGs, Ensembl [20,21] has 
adapted their browser. NCBI supports displays of LRG 
sequences and reported variants using client software 
(NCBI Genome Workbench [22]) and the graphical se-
quence viewer [23]. Use of these tools facilitates integra-
tion of LRG data variant data in dbSNP (NCBI Database 
of Genetic Variation) [24,25]. Th  e NGRL Universal 
Browser (National Genetics Reference Laboratory, Man-
chester;) already provides a graphical view of LRGs [26] 
with the ability, for some genes, to display tracks linked 
to dbSNP and to appropriate LSDBs.
A major issue with variant curation is how DNA 
sequences might be visualized to make the process 
simpler and less prone to error. Journal editors and 
referees are well aware of the frequency with which 
authors report variants erroneously. Ideally, a browser 
will be developed that will integrate fully with the 
commonly used LSDB systems, such as LOVD (Leiden 
Open Variation Database) [27,28], UMD (Universal 
Mutation Database) [29,30] and MUTbase (Maintenance 
and Analysis of Mutation Databases on the World Wide 
Web) [31,32], allowing curators and submitters to auto-
matically generate standards-compliant variant descrip-
tions using the LRG sequences as a reporting reference 
standard.
Tools such as Mutalyzer [33,34], both in its standalone 
form and through the API used by the LOVD variant 
database system, have made the process of correctly 
naming variants relative to all annotated transcripts and 
protein isoforms much simpler, but more sophisticated 
variant-visualization systems would be a welcome 
development. Just as with Mutalyzer, such systems would 
parse the annotated features of reference DNA sequences 
to provide the necessary visual cues to help generate an 
HGVS-nomenclature-compliant description of any 
variant. Ideally, such a system would incorporate cross-
checking with legacy numbering systems. To achieve 
this, a robust and comprehensive feature-annotation 
scheme with a controlled vocabulary will be essential. 
Th  e LRG speciﬁ   cation does not speciﬁ   cally entail the 
produc  tion of a dedicated sequence browser, but produ-
cing one that uses LRG sequences would facilitate the 
successful adoption of LRGs. To this end, the LRG XML 
schema is fully open and has version control, allowing 
any party, commercial or public, to develop visualization 
tools.
Closing remarks
Th   e LRG speciﬁ  cation is the culmination of considerable 
debate among those participating in the project and has 
also been fashioned by the advice of external com  men-
tators. Most of the proposals have been accepted readily, 
but two in particular have been controversial. Th  e  ﬁ  rst is 
the proposal to allow addition of transcripts to the ﬁ  xed-
annotation layer. Th  e argument is that this amounts to 
versioning and does not solve the existing version 
problem. Versioning is an issue with traditional reference 
sequence records because the actual sequences diﬀ  er 
from version to version for records with the same 
accession number. In the ﬁ  xed-annotation layer of the 
LRG, the sequence data for the genomic DNA, the 
transcripts and their translation products will never be 
changed or removed. Consequently, a variant description 
such as LRG_13:g.8290C>A will always remain valid and 
will not be subject to misinterpretation.
Likewise, the proposal to allow more than one LRG for 
the same gene region has also provoked similar argu-
ments about versioning. If it is no longer possible to 
describe a sequence variant in terms of an existing LRG, 
it might be necessary to create a totally new LRG with a 
uniquely diﬀ   erent number (for example, LRG_1275 
instead of the existing LRG_89). Th  e original LRG will 
not be ‘retired’ and it will remain valid to describe 
variants with respect to that sequence record. Creation of 
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will only be considered in the most exceptional circum-
stances and each will be cross-referenced with the other 
in the updatable annotation layer.
Finally, queries have been raised about the ability of 
LRGs to support the reporting of copy number variation 
(CNV). LRGs are no less well suited to the task of CNV 
description than existing reference sequence records. 
Requests will be considered for the creation of a new 
LRG representing a particular allele with respect to CNV 
and we will work with the requesting party to achieve the 
best practicable solution to represent the allele. Again, 
this will only be considered in the most exceptional 
circumstances. Th  e issues that have been raised during 
the development of the LRG speciﬁ  cation are the subject 
of a frequently asked questions (FAQs) page, accessible 
from the LRG home page.
In the absence of any proposals of alternative solutions 
to deal with these issues, we feel that LRGs provide a 
pragmatic solution to the needs of LSDBs and clinical 
laboratories with respect to reporting sequence variants 
in a stable fashion.
LRG timeline
Initial discussion of the need for improved reference 
sequences suited to the task of curation of variants in 
LSDBs took place at the ﬁ  rst general assembly meeting of 
the GEN2PHEN project in January 2008. Immediately 
following that meeting, a survey was distributed to LSDB 
curators through the HGVS and the results were analyzed 
in March 2008. In April 2008, a two-day workshop was 
held at EBI to formulate the speciﬁ  cation of an improved 
reference sequence that is now known as Locus Reference 
Genomic (LRG). Creation of the formal LRG speciﬁ  cation 
began in May 2008 and several versions were produced in 
response to internal discussion and to feedback elicited 
through the HGVS. Th   e current version (version 12) was 
agreed in June 2009.
Creation and revision of the LRG XML schema began 
in March 2009 (currently at version 1.6) and the ﬁ  rst LRG 
records were created in June 2009. At present, LRGs have 
been ﬁ  nalized for ten genes and a further four await ﬁ  nal 
approval. Requests have been received for approximately 
90 additional genes and these are currently in production. 
We invite enquiries concerning the creation of additional 
LRGs.
Availability
Access to further information and to LRG sequence 
records is available at [15]. A search facility is provided 
and there is a link to frequently asked questions (FAQs). 
Speciﬁ  c links are provided to request technical support, 
to request the creation of new LRGs and to allow 
feedback on the LRG speciﬁ  cation.
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